Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors

Behavioural Brain Research

Volumn 303, Issue , 2016, Pages 218-227

  Sartim, A G ^a   Guimaraes F S ^a   Joca, S R L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

5HT1A; Antidepressant; Cannabidiol; Forced swimming test; vmPFC

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ANANDAMIDE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR; AMIDE; ANTIDEPRESSANT AGENT; ARACHIDONIC ACID DERIVATIVE; ENDOCANNABINOID; N-(2-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)ETHYL)-N-(2-PYRIDINYL)CYCLOHEXANECARBOXAMIDE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN 1 AGONIST; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FORCED SWIM TEST; INFRALIMBIC CORTEX; LOCOMOTION; MALE; MICROINJECTION; NONHUMAN; OPEN FIELD TEST; PRELIMBIC CORTEX; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT; SEROTONINERGIC SYSTEM; STRESS; AGONISTS; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; MOTOR ACTIVITY; PHYSIOLOGY; PREFRONTAL CORTEX; WISTAR RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTIDEPRESSIVE AGENTS; ARACHIDONIC ACIDS; BEHAVIOR, ANIMAL; CANNABIDIOL; ENDOCANNABINOIDS; MALE; MOTOR ACTIVITY; PIPERAZINES; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PREFRONTAL CORTEX; PYRAZOLES; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN ANTAGONISTS;

EID: 84960413411     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2016.01.033     Document Type: Article

References (62)

1. Guimarães F.S., Chiaretti T.M., Graeff F.G., Zuardi A.W. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl.) 1990, 100:558-559.
2. Resstel L.B., Tavares R.F., Lisboa S.F., Joca S.R., Corrêa F.M., Guimarães F.S. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br. J. Pharmacol. 2009, 156:181-188.
3. Carlini E.A., Cunha J.M. Hypnotic and antiepileptic effects of cannabidiol. J. Clin. Pharmacol. 1981, 21:417S-427S.
4. Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gagliardi R., Sanvito W.L., Lander N., Mechoulam R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980, 21:175-185.
5. Jones N.A., Hill A.J., Smith I., Bevan S.A., Williams C.M., Whalley B.J., Stephens G.J. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J. Pharmacol. Exp. Ther. 2010, 332(2):569-577.
6. Casarotto P.C., Gomes F.V., Resstel L.B., Guimarães F.S. Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors. Behav. Pharmacol. 2010, 21:353-358.
7. Zuardi A.W., Rodrigues J.A., Cunha J.M. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl.) 1991, 104:260-264.
8. Zuardi A.W., Crippa J.A., Hallak J.E., Moreira F.A., Guimarães F.S. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz. J. Med. Biol. Res. 2006, 39:421-429.
9. Zanelati T.V., Biojone C., Moreira F.A., Guimarães F.S., Joca S.R. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br. J. Pharmacol. 2010, 159:122-128.
10. El-Alfy A.T., Ivey K., Robinson K., Ahmed S., Radwan M., Slade D., Khan I., ElSohly M., Ross S. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol. Biochem. Behav. 2010, 95:434-442.
11. Campos A.C., Moreira F.A., Gomes F.V., Del Bel E.A., Guimarães F.S. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2012, 367:3364-3378.
12. Petitet F., Jeantaud B., Reibaud M., Imperato A., Dubroeucq M.C. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci. 1998, 63:PL1-6.
13. Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde D.E., Brandi I., Moriello A.S., Davis J.B., Mechoulam R., Di Marzo V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 2001, 134:845-852.
14. Watanabe K., Ogi H., Nakamura S., Kayano Y., Matsunaga T., Yoshimura H., Yamamoto I. Distribution and characterization of anandamide amidohydrolase in mouse brain and liver. Life Sci. 1998, 62:1223-1229.
15. Fernández-Ruiz J., Sagredo O., Pazos M.R., García C., Pertwee R., Mechoulam R., Martínez-Orgado J. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?. Br. J. Clin. Pharmacol. 2013, 75:323-333.
16. Campos A.C., Ortega Z., Palazuelos J., Fogaça M.V., Aguiar D.C., Díaz-Alonso J., Ortega-Gutiérrez S., Vázquez-Villa H., Moreira F.A., Guzmán M., Galve-Roperh I., Guimarães F.S. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int. J. Neuropsychopharmacol. 2013, 16:1407-1419.
17. Russo E.B., Burnett A., Hall B., Parker K.K. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 2005, 30:1037-1043.
18. Rock E.M., Bolognini D., Limebeer C.L., Cascio M.G., Anavi-Goffer S., Fletcher P.J., Mechoulam R., Pertwee R.G., Parker L.A. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br. J. Pharmacol. 2012, 165(8):2620-2634.
19. Hayakawa K., Mishima K., Nozako M., Ogata A., Hazekawa M., Liu A.X., Fujioka M., Abe K., Hasebe N., Egashira N., Iwasaki K., Fujiwara M. Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. Neuropharmacology 2007, 52:1079-1087.
20. Campos A.C., Guimarães F.S. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl.) 2008, 199:223-230.
21. Bambico F.R., Katz N., Debonnel G., Gobbi G. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J. Neurosci. 2007, 27:11700-11711.
22. Bambico F.R., Cassano T., Dominguez-Lopez S., Katz N., Walker C.D., Piomelli D., Gobbi G. Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus. Neuropsychopharmacology 2010, 35:2083-2100.
23. 1 receptor in the modulation of stress coping behavior in mice: the role of serotonin and different forebrain neuronal subpopulations. Neuropharmacology 2013, 65:83-89.
24. Liston C., Miller M.M., Goldwater D.S., Radley J.J., Rocher A.B., Hof P.R., Morrison J.H., McEwen B.S. Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. J. Neurosci. 2006, 26:7870-7874.
25. Beeman C.L., Bauer P.S., Pierson J.L., Quinn J.J. Hippocampus and medial prefrontal cortex contributions to trace and contextual fear memory expression over time. Learn. Mem. 2013, 20:336-343.
26. Resstel L.B., Joca S.R., Guimarães F.G., Corrêa F.M. Involvement of medial prefrontal cortex neurons in behavioral and cardiovascular responses to contextual fear conditioning. Neuroscience 2006, 143:377-385.
27. Kesner R.P., Churchwell J.C. An analysis of rat prefrontal cortex in mediating executive function. Neurobiol. Learn. Mem. 2011, 96:417-431.
28. Vertes R.P. Differential projections of the infralimbic and prelimbic cortex in the rat. Synapse 2004, 51:32-58.
29. Sangha S., Robinson P.D., Greba Q., Davies D.A., Howland J.G. Alterations in reward fear and safety cue discrimination after inactivation of the rat prelimbic and infralimbic cortices. Neuropsychopharmacology 2014.
30. Burgos-Robles A., Bravo-Rivera H., Quirk G.J. Prelimbic and infralimbic neurons signal distinct aspects of appetitive instrumental behavior. PLoS One 2013, 8:e57575.
31. Scopinho A.A., Scopinho M., Lisboa S.F., Correa F.M., Guimarães F.S., Joca S.R. Acute reversible inactivation of the ventral medial prefrontal cortex induces antidepressant-like effects in rats. Behav. Brain Res. 2010, 214:437-442.
32. Hamani C., Diwan M., Macedo C.E., Brandão M.L., Shumake J., Gonzalez-Lima F., Raymond R., Lozano A.M., Fletcher P.J., Nobrega J.N. Antidepressant-like effects of medial prefrontal cortex deep brain stimulation in rats. Biol. Psychiatry 2010, 67:117-124.
33. Savitz J., Lucki I., Drevets W.C. 5-HT(1A) receptor function in major depressive disorder. Prog. Neurobiol. 2009, 88:17-31.
34. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 2002, 23(5):238-245.
35. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, London.
36. Joca S.R., Guimarães F.S. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology (Berl.) 2006, 185:298-305.
37. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
38. Slattery D.A., Cryan J.F. Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat. Protoc. 2012, 7:1009-1014.
39. Abel E.L., Bilitzke P.J. A possible alarm substance in the forced swimming test. Physiol. Behav. 1990, 48:233-239.
40. Gabbott P.L., Warner T.A., Jays P.R., Bacon S.J. Areal and synaptic interconnectivity of prelimbic (area 32), infralimbic (area 25) and insular cortices in the rat. Brain Res. 2003, 993:59-71.
41. Yuen E.Y., Wei J., Liu W., Zhong P., Li X., Yan Z. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron 2012, 73:962-977.
42. Silva M., Aguiar D.C., Diniz C.R., Guimarães F.S., Joca S.R. Neuronal NOS inhibitor and conventional antidepressant drugs attenuate stress-induced fos expression in overlapping brain regions. Cell. Mol. Neurobiol. 2012, 32:443-453.
43. Barbas H. Anatomic basis of cognitive-emotional interactions in the primate prefrontal cortex. Neurosci. Biobehav. Rev. 1995, 19:499-510.
44. Vidal-Gonzalez I., Vidal-Gonzalez B., Rauch S.L., Quirk G.J. Microstimulation reveals opposing influences of prelimbic and infralimbic cortex on the expression of conditioned fear. Learn. Mem. 2006, 13:728-733.
45. Tavares R.F., Corrêa F.M., Resstel L.B. Opposite role of infralimbic and prelimbic cortex in the tachycardiac response evoked by acute restraint stress in rats. J. Neurosci. Res. 2009, 87:2601-2607.
46. Radley J.J., Arias C.M., Sawchenko P.E. Regional differentiation of the medial prefrontal cortex in regulating adaptive responses to acute emotional stress. J. Neurosci. 2006, 26:12967-12976.
47. Marquis J.P., Killcross S., Haddon J.E. Inactivation of the prelimbic, but not infralimbic, prefrontal cortex impairs the contextual control of response conflict in rats. Eur. J. Neurosci. 2007, 25:559-566.
48. Heidbreder C.A., Groenewegen H.J. The medial prefrontal cortex in the rat: evidence for a dorso-ventral distinction based upon functional and anatomical characteristics. Neurosci. Biobehav. Rev. 2003, 27:555-579.
49. Campos A.C., Ferreira F.R., Guimarães F.S. Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors. J. Psychiatr. Res. 2012, 46:1501-1510.
50. Mishima K., Hayakawa K., Abe K., Ikeda T., Egashira N., Iwasaki K., Fujiwara M. Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke 2005, 36:1077-1082.
51. Thomas A., Baillie G.L., Phillips A.M., Razdan R.K., Ross R.A., Pertwee R.G. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 2007, 150(5):613-623.
52. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., Cassano T., Morgese M.G., Debonnel G., Duranti A., Tontini A., Tarzia G., Mor M., Trezza V., Goldberg S.R., Cuomo V., Piomelli D. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18620-18625.
53. Jankowski M.P., Sesack S.R. Prefrontal cortical projections to the rat dorsal raphe nucleus: ultrastructural features and associations with serotonin and gamma-aminobutyric acid neurons. J. Comp. Neurol. 2004, 468:518-529.
54. Chalmers D.T., Watson S.J. Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain-a combined in situ hybridisation/in vitro receptor autoradiographic study. Brain Res. 1991, 561:51-60.
55. Burnet P.W., Eastwood S.L., Lacey K., Harrison P.J. The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res. 1995, 676:157-168.
56. Wieland S., Lucki I. Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test. Psychopharmacology (Berl.) 1990, 101:497-504.
57. Cryan J.F., Redmond A.M., Kelly J.P., Leonard B.E. The effects of the 5-HT1A agonist flesinoxan, in three paradigms for assessing antidepressant potential in the rat. Eur. Neuropsychopharmacol. 1997, 7:109-114.
58. Carr G.V., Lucki I. The role of serotonin receptor subtypes in treating depression: a review of animal studies. Psychopharmacology (Berl.) 2011, 213:265-287.
59. Haddjeri N., Blier P., de Montigny C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J. Neurosci. 1998, 18:10150-10156.
60. López-Gil X., Artigas F., Adell A. Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex. Curr. Pharm. Des. 2010, 16:502-515.
61. Araneda R., Andrade R. 5-Hydroxytryptamine2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 1991, 40:399-412.
62. Pereira V.S., Romano A., Wegener G., Joca S.R. Antidepressant-like effects induced by NMDA receptor blockade and NO synthesis inhibition in the ventral medial prefrontal cortex of rats exposed to the forced swim test. Psychopharmacology (Berl.) 2015, [Epub ahead of print] PubMed PMID: 25589143.